Thyrocare Technologies Q2 FY27 Results: Consolidated Net Profit ₹15.22 Crore on Total Income of ₹274 Crore
Earnings
Diagnostics
Blacklitt Research3 min read
Thyrocare Technologies (NSE: THYROCARE) reported consolidated total income of ₹274.44 crore and net profit of ₹15.22 crore for the quarter ended 30 Sep 2026, a fall from ₹47.81 crore a year earlier, it said in a filing on 29 Oct 2026. Standalone net profit for the quarter was ₹48.13 crore on total income of ₹259.19 crore.
Key highlights
Consolidated
Including its subsidiaries
Total income: ₹274.44 crore, up 25.0% YoY and 12.4% QoQ
Net profit: ₹15.22 crore, down 68.2% YoY and 70.3% QoQ
EPS: ₹0.96 basic, against ₹3.00 a year earlier
Exceptional item: ₹44.98 crore impairment on the NHL investment
Standalone
The company on its own, without its subsidiaries
Total income: ₹259.19 crore, up 26.7% YoY and 13.1% QoQ
Net profit: ₹48.13 crore, up 11.9% YoY and down 4.1% QoQ
EPS: ₹3.03 basic, against ₹2.70 a year earlier
Exceptional item: ₹9.17 crore impairment on the NHL investment
Summary
Consolidated ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
274.44
219.58
+25.0%
244.17
+12.4%
Revenue from operations
270.81
216.53
+25.1%
240.02
+12.8%
Other income
3.63
3.05
+19.0%
4.15
-12.5%
15.22
47.81
-68.2%
51.33
-70.3%
Profit before tax
33.65
62.58
-46.2%
68.29
-50.7%
Finance costs
1.57
0.59
+166.1%
1.35
+16.3%
Depreciation
13.52
11.51
+17.5%
12.49
+8.2%
Tax expense
18.43
14.77
+24.8%
16.96
+8.7%
Net profit margin
5.55%
21.77%
-16.23 pp
21.02%
-15.48 pp
EPS, basic (₹)
0.96
3.00
-68.0%
3.22
-70.2%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated net profit fell 68.2% YoY while total income rose 25.0%. The gap sits below the operating line: profit before tax fell 46.2% to ₹33.65 crore, and the consolidated statement shows an exceptional item of ₹44.98 crore, which the company describes as an additional impairment loss on its investment in Nueclear Healthcare Limited after a latest valuation report.
Revenue from operations rose 25.1%, faster than other income, which rose 19.0%. Other income of ₹3.63 crore is 1.3% of total income. Tax expense of ₹18.43 crore is 54.8% of profit before tax, so the tax charge is larger than the pre-tax profit's share would suggest, and the statement does not give a reason for the tax rate.
Finance costs rose to ₹1.57 crore from ₹0.59 crore a year earlier, and depreciation rose 17.5% to ₹13.52 crore. Finance costs are 0.6% of total income. The filing does not explain the rise in either line.
Standalone ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
259.19
204.51
+26.7%
229.17
+13.1%
Revenue from operations
256.25
202.23
+26.7%
225.66
+13.6%
Other income
2.94
2.28
+28.9%
3.51
-16.2%
48.13
43.03
+11.9%
50.17
-4.1%
Profit before tax
65.83
60.89
+8.1%
66.63
-1.2%
Finance costs
1.48
0.60
+146.7%
1.26
+17.5%
Depreciation
12.50
9.70
+28.9%
11.23
+11.3%
Tax expense
17.70
17.86
-0.9%
16.46
+7.5%
Net profit margin
18.57%
21.04%
-2.47 pp
21.89%
-3.32 pp
EPS, basic (₹)
3.03
2.70
+12.2%
3.15
-3.8%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 11.9% YoY, slower than total income, which rose 26.7%, and faster than profit before tax, which rose 8.1%. Tax expense fell 0.9% to ₹17.70 crore against ₹17.86 crore a year earlier, while profit before tax rose to ₹65.83 crore from ₹60.89 crore. Standalone profit is after a ₹9.17 crore exceptional impairment on the same NHL investment.
Standalone revenue from operations rose 26.7%, slower than other income, which rose 28.9%. Other income of ₹2.94 crore is 4.5% of profit before tax.
Consolidated segment revenue for the quarter was ₹256.74 crore from diagnostic testing services, ₹13.55 crore from imaging services and ₹0.52 crore from other businesses. The filing does not give segment profit for the quarter in the text read.
The company says the sale is for cash and Compulsorily Convertible Preference Shares of approximately ₹141.40 crore, subject to working capital adjustments. Shareholder approval, including a majority of public shareholders, was pending at 30 Sep 2026, so the investment was not classified as held for sale. The postal ballot e-voting ran from 30 Sep 2026 to 29 Oct 2026.
Inference
The filing reports a dividend of ₹111.42 crore paid to shareholders in the six months to 30 Sep 2026, and a consolidated paid-up share capital of ₹159.17 crore. The filing does not give the outcome of the postal ballot on the NHL sale or the date it is expected to complete, and it does not say why the sale is proposed or what effect it will have on results.
The auditors issued unmodified limited review conclusions on both sets of results. They note three subsidiaries and one associate that were not reviewed by their auditors, and say these are not material to the group.
Create a free account to read the rest of this article and the analysis that follows.
By continuing you agree to our Terms and Privacy Policy, and to receive updates from Blacklitt by email. You can unsubscribe anytime.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
THYROCAREThyrocare Technologies Ltd.
